Ticker brief
PBM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
26
authors 14d
7
crowd 14d
+0.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-15 · now +0.30 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @beach_trades | C | -2.97 | 20 | +0.42 |
| @theflynews | C | · | 1 | +0.35 |
| @CHItrader | B | -0.22 | 1 | +0.35 |
| @CrweWorld | C | · | 1 | +0.30 |
| @GetPursa | C | +0.10 | 1 | +0.40 |
| @PrismMarketView | C | · | 1 | +0.20 |
| @PrismDM | A | -2.76 | 1 | +0.20 |
Recent signals26of 26 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @beach_trades | +0.30 | Reports that a nearly 50% stake was taken. | · | tweet ↗ |
| 2026-10-13 | @beach_trades | +0.50 | Highlights PBM as an ibogaine pure play and says TCRT is drawing biotech attention. | · | tweet ↗ |
| 2026-10-13 | @beach_trades | +0.55 | Author calls PBM a biased second choice based on possible political support for ibogaine. | · | tweet ↗ |
| 2026-10-12 | @beach_trades | +0.20 | Highlights PBM as a pure-play ibogaine company. | · | tweet ↗ |
| 2026-10-08 | @beach_trades | +0.40 | Reports advancement of the first U.S. government-funded ibogaine trials, presented as relevant to PBM. | · | tweet ↗ |
| 2026-10-08 | @beach_trades | +0.20 | Reports that Psyence BioMed met with the FDA, but gives no specific regulatory outcome. | · | tweet ↗ |
| 2026-10-08 | @beach_trades | +0.20 | Flags November 20, 2026 as a PBM catalyst date without specifying the event. | · | tweet ↗ |
| 2026-10-08 | @beach_trades | +0.40 | Reports FDA advancement of government-funded ibogaine trials for opioid addiction and PTSD. | · | tweet ↗ |
| 2026-10-08 | @beach_trades | +0.70 | Expresses strong optimism that a catalyst is approaching for pure-play ibogaine name PBM. | · | tweet ↗ |
| 2026-10-08 | @beach_trades | +0.60 | Favor ENVB and PBM into the midterm elections on expected psychedelic-policy support. — Explicitly likes both stocks into a defined political catalyst window. | · | tweet ↗ |
| 2026-10-05 | @PrismDM | +0.20 | Psyence subsidiary partnered with Benuvia on a US ibogaine manufacturing pathway. | · | tweet ↗ |
| 2026-10-05 | @PrismMarketView | +0.20 | Reports a manufacturing agreement for planned U.S. ibogaine API production, subject to permits. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.20 | Expects ENVB to move next after PBM. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.55 | Predicts PBM will break the $7 level. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.75 | Speculates PBM will be acquired at a massive premium due to its ibogaine focus. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.35 | Says PBM's 50-day moving average is in play. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.25 | Links PBM to growing global interest in Gabon's ibogaine resource. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.45 | Frames Benuvia's controlled-substance manufacturing experience as a moat for PBM. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.35 | Psyence BioMed announced a manufacturing partnership with Benuvia for ibogaine. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.65 | Calls Benuvia's DEA-registered manufacturing facility a major positive for PBM. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.45 | Cites Stanford study outcomes supporting ibogaine's potential relevance to PBM. | · | tweet ↗ |
| 2026-10-05 | @beach_trades | +0.40 | Psyence signed a manufacturing-services agreement for planned U.S. ibogaine API production. | · | tweet ↗ |
| 2026-10-05 | @GetPursa | +0.40 | Psyence signed Benuvia for US pharmaceutical-grade ibogaine API manufacturing services. | · | tweet ↗ |
| 2026-10-05 | @CrweWorld | +0.30 | Psyence BioMed partners with Benuvia for U.S. pharmaceutical-grade ibogaine manufacturing. | · | tweet ↗ |
| 2026-10-05 | @CHItrader | +0.35 | Psyence signed Benuvia to manufacture pharmaceutical-grade ibogaine API in the US. | · | tweet ↗ |
| 2026-10-03 | @theflynews | +0.35 | Reports an exclusive U.S. ibogaine license and shipment of a drug candidate. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.